New Sino/Norwegian Pharma Company
The Shanghai Huaihai Drug Factory in the Chinese city of Shanghai and an unspecified Norwegian pharmaceutical company have signed an agreement for the establishment of the Shanghai Naike Pharmaceutical Co Ltd in the Pudong Zhangjian Hightech Science and Technological Park in Shanghai, reports the China Foreign Trade journal.
The joint venture, which is said to have a total investment of $30 million, will produce various pharmaceuticals and associated raw materials. It is believed to be the first Norwegian-funded pharmaceutical joint venture in China.
- Sandoz of Switzerland has negotiated two joint ventures in China with the Tianjin No 5 Dyestuff Chemicals Factory, involving overall $30 million investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze